Abstract

Exploring Hybrid Molecules as Multifunctional Treatments for Alzheimer\'s Disease

Author(s): Nikhil Musale* and Bagade Shashikant

Alzheimer's Disease (AD) is one of the most common health conditions in the world and affect neurons and changes several proteins. Based on the 35.6 million of AD cases reported to the world in 2011, the current clinical single molecule treatment of single drug targets single disease component has not been proved to be effective enough and researchers and practitioners are nowadays working together according to the principle of collaboration and focusing on the necessity of collaboration, in order to give a single molecule to multiple disease processes, that is, to nerve cell death. In recent years’ medicinal chemists have been working together to design along with synthesize hybrid molecules. These molecules represent the optimal composition for generating two pharmacologically usable fragments of two oppositely acting chemical species. Alzheimer's Disease (AD), with a continuously increasing global health challenge, is caused by neuronal death and malfunction of various types of proteins. As a global AD population (i.e., approximately 35.6 million AD patients) 2011, collaboration in the medical, scientific and policy spheres is of extreme urgency. The conventional isolated drug "drugs-diseases-drugs" theory of how one drug controls a specific symptom for a single disease has been found inadequate. A multitude of compounds have been screened, such as donepezil-AP2238 hybrids, some donepezil analogues, some tacrine hybrids, galantamine/memantine co-preparation, some rivastigmine hybrids, some physostigmine hybrids and so on.

PDF

30+ Million Readerbase

Google Scholar citation report

Citations : 15261

Der Pharma Chemica received 15261 citations as per Google Scholar report

Der Pharma Chemica peer review process verified at publons